CA2757743C — (2'-deoxy-ribofuranosyl)-1,3,4,7-tetrahydro-(1,3) diazepin-2-0ne derivatives for treating cancer
Assigned to Otsuka Pharmaceutical Co Ltd · Expires 2017-10-10 · 9y expired
What this patent protects
The invention relates to the compound of formula I: (see formula I) wherein: one of R1 and R2 is F, and the other is selected from H and F; one of R3 and R4 is H, and the other is selected from H and OH; where ------- is a covalent bond or absent, and R4 is absent when ------- is…
USPTO Abstract
The invention relates to the compound of formula I: (see formula I) wherein: one of R1 and R2 is F, and the other is selected from H and F; one of R3 and R4 is H, and the other is selected from H and OH; where ------- is a covalent bond or absent, and R4 is absent when ------- is a covalent bond; or a pharmaceutically acceptable C1-6 alkyl ester or a C2-6 alkenyl ester thereof. The compound may be used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.